Meta-Analysis
Copyright ©The Author(s) 2015.
World J Gastroenterol. May 7, 2015; 21(17): 5382-5392
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5382
Table 1 Characteristics of the studies included in the meta-analysis
Ref.Country/regionRisk factorsPpis
Control
Peptic ulcer
UGIB
MACE
Diarrhea
DrugnDose (mg/d)DrugnDose (mg/d)PPIControlPPIControlPPIControlPPIControl
Lai et al[3]Hong KongADA-induced ulcersLansoprazole6230Placebo61-1908----
H. pylori eradicated
Yeomans et al[4]10 countriesAged ≥ 60, withoutEsomeprazole49320Placebo498-82724814--
ulcer
Bhatt et al[5]15 countriesCombined with clopidogrelOmeprazole187620Placebo1885-2682655545634
Ren et al[6]ChinaCombined with clopidogrelOmeprazole8620Placebo86---022222--
Scheiman et al[8]20 countriesH. pylori-negative, high riskEsomeprazole162320-40Placebo804-195313114818
Sugano et al[9]JapanWith a history of ulcerLansoprazole22615Gefarnate23510065329--192
Sanuki et al[7]JapanWith a history of ulcerRabeprazole17610-20Gefarnate8510092001----
Ng et al[12]Hong KongAspirin-related ulcers/erosionsPantoprazole6520Famotidine65800605----
Ng et al[11]Hong KongCombined with clopidogrelEsomeprazole16320Famotidine148401531275--
Yano et al[10]JapanCombined with clopidogrelOmeprazole6510Famotidine6520--31811--